// App-Quantinova.ai

: In-vitro product performance of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) delivered from a dry powder inhaler (DPI) using the Electronic Lung (EL) to replicate patient inhalation profiles

Researchers

Presenter

  • David Prime

Principal Investigators

  • Melanie Hamilton

  • Edward Taylor

Medical Centers

  • GlaxoSmithKline plc., R&D, Drug Product Design and Development, Ware, Hertfordshire, SG12 0DP United Kingdom, Ware, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Fluticasone furoate

  • Umeclidinium

  • Fluticasone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved